The Antiviral, Daclatasvir, Downregulates Tribbles 2 Pseudokinase and Reverses Enzalutamide Resistance in Prostate Cancer (ET_152)
Location
Buerki Auditorium, Henry Ford Hospital
Start Date
17-5-2024 10:00 AM
End Date
17-5-2024 10:15 AM
Description
Session 2: Juried Abstracts for Oral Presentations; Moderated by Shyam Nyati and Sushmitha Sriramulu; Margot C. LaPointe Early Career Investigator Award Winner
Recommended Citation
Monga, Jitender; Guddeti, Rohith K.; Rogers, Craig; and Gadgeel, Shirish, "The Antiviral, Daclatasvir, Downregulates Tribbles 2 Pseudokinase and Reverses Enzalutamide Resistance in Prostate Cancer (ET_152)" (2024). Henry Ford Medical Group Research Symposium. 7.
https://scholarlycommons.henryford.com/hfmgrs/2024/Program/7
The Antiviral, Daclatasvir, Downregulates Tribbles 2 Pseudokinase and Reverses Enzalutamide Resistance in Prostate Cancer (ET_152)
Buerki Auditorium, Henry Ford Hospital
Session 2: Juried Abstracts for Oral Presentations; Moderated by Shyam Nyati and Sushmitha Sriramulu; Margot C. LaPointe Early Career Investigator Award Winner
